35 88

Cited 1 times in

Association of sodium-glucose cotransporter 2 inhibitors with post-discharge outcomes in patients with acute heart failure with type 2 diabetes: a cohort study

Authors
 Sohee Park  ;  Han Eol Jeong  ;  Hyesung Lee  ;  Seng Chan You  ;  Ju-Young Shin 
Citation
 CARDIOVASCULAR DIABETOLOGY, Vol.22(1) : 191, 2023-07 
Journal Title
CARDIOVASCULAR DIABETOLOGY
Issue Date
2023-07
MeSH
Aftercare ; Aged ; Cohort Studies ; Diabetes Mellitus, Type 2* / chemically induced ; Diabetes Mellitus, Type 2* / diagnosis ; Diabetes Mellitus, Type 2* / drug therapy ; Female ; Glucose ; Heart Failure* / chemically induced ; Heart Failure* / diagnosis ; Heart Failure* / drug therapy ; Humans ; Male ; Patient Discharge ; Retrospective Studies ; Sodium ; Sodium-Glucose Transporter 2 Inhibitors* / adverse effects
Keywords
Acute heart failure ; Postdischarge Outcome ; Sodium-glucose cotransporter 2 inhibitors ; Type 2 diabetes
Abstract
Background: Given the cumulative evidence on the effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2is) on chronic heart failure, demand is emerging for further information on their effects in patients who are hospitalized for acute heart failure. However, there is still limited evidence about the class effect of SGLT2is on acute heart failure. We investigated whether initiating treatment with SGLT2is after an episode of acute heart failure reduces the risks of post-discharge heart failure readmission or cardiovascular mortality among patients with type 2 diabetes.

Methods: A retrospective cohort study was conducted in a cohort of patients with type 2 diabetes who hospitalized for heart failure, using Korean Health Insurance Review & Assessment database (2015-2020). The exposure was defined as initiation of SGLT2is during hospitalization or at discharge. We assessed hazards of post-discharge heart failure readmission and cardiovascular death at 1-year, and 30-, 60-, and 90-day from the date of discharge in the SGLT2is users and non-users. Cox proportional hazards models with propensity score-based inverse probability of treatment weighting were used to estimate hazard ratios and 95% confidence intervals.

Results: Among 56,343 patients with type 2 diabetes hospitalized for heart failure, 29,290 patients were included in the study cohort (mean [SD] age, 74.1 [10.8] years; 56.1% women); 818 patients (2.8%) were prescribed SGLT2is during index hospitalization or at discharge. Patients with a prescription for SGLT2i vs. those without prescription had lower rates of heart failure readmission or cardiovascular death at 1 year (22.4% vs. 25.3%; adjusted hazard ratio, 0.90 [95% confidence interval, 0.87-0.93]), and also at 30 days (7.0% vs. 7.7%%; 0.74 [0.69-0.79]).

Conclusions: Among patients with type 2 diabetes, initiating SGLT2i treatment after an episode of acute heart failure was significantly associated with a reduced combined risk of heart failure readmission and cardiovascular mortality in a nationwide cohort reflecting routine clinical practice.
Files in This Item:
T202307306.pdf Download
DOI
10.1186/s12933-023-01896-3
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) > 1. Journal Papers
Yonsei Authors
You, Seng Chan(유승찬) ORCID logo https://orcid.org/0000-0002-5052-6399
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/197268
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links